APA
Albright C. F., Graciani N., Han W., Yue E., Stein R., Lai Z., Diamond M., Dowling R., Grimminger L., Zhang S., Behrens D., Musselman A., Bruckner R., Zhang M., Jiang X., Hu D., Higley A., Dimeo S., Rafalski M., Mandlekar S., Car B., Yeleswaram S., Stern A., Copeland R. A., Combs A., Seitz S. P., Trainor G. L., Taub R., Huang P. & Oliff A. (20050809). Matrix metalloproteinase-activated doxorubicin prodrugs inhibit HT1080 xenograft growth better than doxorubicin with less toxicity. : Molecular cancer therapeutics.
Chicago
Albright Charles F, Graciani Nilsa, Han Wei, Yue Eddy, Stein Ross, Lai Zhihong, Diamond Melody, Dowling Randine, Grimminger Lisa, Zhang Shu-Yun, Behrens Davette, Musselman Amy, Bruckner Robert, Zhang Mingzhu, Jiang Xiang, Hu Daniel, Higley Anne, Dimeo Susan, Rafalski Maria, Mandlekar Sandya, Car Bruce, Yeleswaram Swamy, Stern Andrew, Copeland Robert A, Combs Andrew, Seitz Steve P, Trainor George L, Taub Rebecca, Huang Pearl and Oliff Allen. 20050809. Matrix metalloproteinase-activated doxorubicin prodrugs inhibit HT1080 xenograft growth better than doxorubicin with less toxicity. : Molecular cancer therapeutics.
Harvard
Albright C. F., Graciani N., Han W., Yue E., Stein R., Lai Z., Diamond M., Dowling R., Grimminger L., Zhang S., Behrens D., Musselman A., Bruckner R., Zhang M., Jiang X., Hu D., Higley A., Dimeo S., Rafalski M., Mandlekar S., Car B., Yeleswaram S., Stern A., Copeland R. A., Combs A., Seitz S. P., Trainor G. L., Taub R., Huang P. and Oliff A. (20050809). Matrix metalloproteinase-activated doxorubicin prodrugs inhibit HT1080 xenograft growth better than doxorubicin with less toxicity. : Molecular cancer therapeutics.
MLA
Albright Charles F, Graciani Nilsa, Han Wei, Yue Eddy, Stein Ross, Lai Zhihong, Diamond Melody, Dowling Randine, Grimminger Lisa, Zhang Shu-Yun, Behrens Davette, Musselman Amy, Bruckner Robert, Zhang Mingzhu, Jiang Xiang, Hu Daniel, Higley Anne, Dimeo Susan, Rafalski Maria, Mandlekar Sandya, Car Bruce, Yeleswaram Swamy, Stern Andrew, Copeland Robert A, Combs Andrew, Seitz Steve P, Trainor George L, Taub Rebecca, Huang Pearl and Oliff Allen. Matrix metalloproteinase-activated doxorubicin prodrugs inhibit HT1080 xenograft growth better than doxorubicin with less toxicity. : Molecular cancer therapeutics. 20050809.